This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Flyvbjerg, A. Articles by Nielsen, O. S. Search for Related Content PubMed PubMed Citation Articles by Flyvbjerg, A. Articles by Nielsen, O. S.

Elevated Serum Insulin-Like Growth Factor-Binding Protein 2 (IGFBP-2) and Decreased IGFBP-3 in Epithelial Ovarian Cancer: Correlation with Cancer Antigen 125 and Tumor-Associated Trypsin Inhibitor¹

Institute of Experimental Clinical Research (A.F.) and Department of Immunoserology, Danish Cancer Society (O.M., B.M.), Department of Oncology (O.M., O.S.N.), Aarhus Kommunehospital, Aarhus University Hospital, DK-8000 Aarhus C, Denmark

Address all correspondence and requests for reprints to: Dr. Allan Flyvbjerg, M.D., D.Sc., Institute of Experimental Clinical Research, Aarhus Kommunehospital, Aarhus University Hospital, DK-8000 Aarhus C, Denmark.

Insulin-like growth factors (IGFs) and IGF-binding proteins (IGFBPs) recently have been shown to play a physiological role in the female genital system, including the ovarian follicular system. However, little is known about the role of the IGF system in malignant ovarian disease. To assess possible mutual correlations between alterations in circulating IGFBP profiles and tumuor markers in patients with epithelial ovarian cancer, we performed an RIA for IGFBP-2 and IGFBP-3 and a Western ligand blotting (WLB) in serum samples from 20 patients with epithelial ovarian cancer, 10 patients with benign ovarian tumors, and 8 healthy age-matched controls. The epithelial ovarian cancer group had a mean IGFBP-2 level that was 253% (RIA) and 105% (WLB) above that of controls. IGFBP-2 even correlated positively with the highly sensitive serum tumor marker, cancer antigen 125 (CA 125) (r = 0.71, P < 0.001) but not with the less sensitive tumor-associated trypsin inhibitor. In contrast, serum IGFBP-3 (by RIA and WLB) was decreased in patients with ovarian cancer, and IGFBP-3 proteolytic activity was detectable in some of the patients. Neither IGFBP-3 nor IGFBP-3 proteolytic activity correlated with CA 125; but the former correlated inversely, and the latter positively, with tumor-associated trypsin inhibitor.

In conclusion, IGFBP-2 levels are high in serum of epithelial ovarian cancer patients, and the increment in serum IGFBP-2 correlates positively with CA 125. Alterations in serum IGFBP-2 levels may, therefore, serve as a potential additional marker for ovarian cancer.

This article has been cited by other articles:

				K. Miyako, L. J. Cobb, M. Francis, A. Huang, B. Peng, J. E. Pintar, H. Ariga, and P. Cohen PAPA-1 Is a Nuclear Binding Partner of IGFBP-2 and Modulates Its Growth-Promoting Actions Mol. Endocrinol., February 1, 2009; 23(2): 169 - 175. [Abstract] [Full Text] [PDF]

				Y. Lin, T. Jiang, K. Zhou, L. Xu, B. Chen, G. Li, X. Qiu, T. Jiang, W. Zhang, and S. W. Song Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas Neuro-oncol, January 1, 2009; 11(5): 468 - 476. [Abstract] [Full Text] [PDF]

				S. S. Tworoger, I-M. Lee, J. E. Buring, M. N. Pollak, and S. E. Hankinson Insulin-like Growth Factors and Ovarian Cancer Risk: A Nested Case-Control Study in Three Cohorts Cancer Epidemiol. Biomarkers Prev., August 1, 2007; 16(8): 1691 - 1695. [Abstract] [Full Text] [PDF]

				R. Chen, T. A. Brentnall, S. Pan, K. Cooke, K. W. Moyes, Z. Lane, D. A. Crispin, D. R. Goodlett, R. Aebersold, and M. P. Bronner Quantitative Proteomics Analysis Reveals That Proteins Differentially Expressed in Chronic Pancreatitis Are Also Frequently Involved in Pancreatic Cancer Mol. Cell. Proteomics, August 1, 2007; 6(8): 1331 - 1342. [Abstract] [Full Text] [PDF]

				S. M. Dunlap, J. Celestino, H. Wang, R. Jiang, E. C. Holland, G. N. Fuller, and W. Zhang Insulin-like growth factor binding protein 2 promotes glioma development and progression PNAS, July 10, 2007; 104(28): 11736 - 11741. [Abstract] [Full Text] [PDF]

				J. L. Olesen, K. M. Heinemeier, C. Gemmer, M. Kjaer, A. Flyvbjerg, and H. Langberg Exercise-dependent IGF-I, IGFBPs, and type I collagen changes in human peritendinous connective tissue determined by microdialysis J Appl Physiol, January 1, 2007; 102(1): 214 - 220. [Abstract] [Full Text] [PDF]

				K. W Frommer, K. Reichenmiller, B. S Schutt, A. Hoeflich, M. B Ranke, G. Dodt, and M. W Elmlinger IGF-independent effects of IGFBP-2 on the human breast cancer cell line Hs578T. J. Mol. Endocrinol., August 1, 2006; 37(1): 13 - 23. [Abstract] [Full Text] [PDF]

				G. K. Wang, L. Hu, G. N. Fuller, and W. Zhang An Interaction between Insulin-like Growth Factor-binding Protein 2 (IGFBP2) and Integrin {alpha}5 Is Essential for IGFBP2-induced Cell Mobility J. Biol. Chem., May 19, 2006; 281(20): 14085 - 14091. [Abstract] [Full Text] [PDF]

				S. Baron-Hay, F. Boyle, A. Ferrier, and C. Scott Elevated Serum Insulin-Like Growth Factor Binding Protein-2 as a Prognostic Marker in Patients with Ovarian Cancer Clin. Cancer Res., March 1, 2004; 10(5): 1796 - 1806. [Abstract] [Full Text] [PDF]

				E. A. Stronach, G. C. Sellar, C. Blenkiron, G. J. Rabiasz, K. J. Taylor, E. P. Miller, C. E. Massie, A. Al-Nafussi, J. F. Smyth, D. J. Porteous, et al. Identification of Clinically Relevant Genes on Chromosome 11 in a Functional Model of Ovarian Cancer Tumor Suppression Cancer Res., December 15, 2003; 63(24): 8648 - 8655. [Abstract] [Full Text] [PDF]

				H. Wang, H. Wang, W. Shen, H. Huang, L. Hu, L. Ramdas, Y.-H. Zhou, W. S-L. Liao, G. N. Fuller, and W. Zhang Insulin-like Growth Factor Binding Protein 2 Enhances Glioblastoma Invasion by Activating Invasion-enhancing Genes Cancer Res., August 1, 2003; 63(15): 4315 - 4321. [Abstract] [Full Text] [PDF]

				S. Kiyama, K. Morrison, T. Zellweger, M. Akbari, M. Cox, D. Yu, H. Miyake, and M. E. Gleave Castration-Induced Increases in Insulin-Like Growth Factor-Binding Protein 2 Promotes Proliferation of Androgen-independent Human Prostate LNCaP Tumors Cancer Res., July 1, 2003; 63(13): 3575 - 3584. [Abstract] [Full Text] [PDF]

				A. Solomon, M. Grueterich, D.-Q. Li, D. Meller, S.-B. Lee, and S. C. G. Tseng Overexpression of Insulin-like Growth Factor-Binding Protein-2 in Pterygium Body Fibroblasts Invest. Ophthalmol. Vis. Sci., February 1, 2003; 44(2): 573 - 580. [Abstract] [Full Text] [PDF]

				S. M. Firth and R. C. Baxter Cellular Actions of the Insulin-Like Growth Factor Binding Proteins Endocr. Rev., December 1, 2002; 23(6): 824 - 854. [Abstract] [Full Text] [PDF]

				J. A. Arraztoa, P. Monget, C. Bondy, and J. Zhou Expression Patterns of Insulin-Like Growth Factor-Binding Proteins 1, 2, 3, 5, and 6 in the Mid-Cycle Monkey Ovary J. Clin. Endocrinol. Metab., November 1, 2002; 87(11): 5220 - 5228. [Abstract] [Full Text] [PDF]

				S. F. Shariat, D. J. Lamb, M. W. Kattan, C. Nguyen, J. Kim, J. Beck, T. M. Wheeler, and K. M. Slawin Association of Preoperative Plasma Levels of Insulin-Like Growth Factor I and Insulin-Like Growth Factor Binding Proteins-2 and -3 With Prostate Cancer Invasion, Progression, and Metastasis J. Clin. Oncol., February 1, 2002; 20(3): 833 - 841. [Abstract] [Full Text] [PDF]

				P Vorwerk, H Wex, B Hohmann, K Mohnike, U Schmidt, and U Mittler Expression of components of the IGF signalling system in childhood acute lymphoblastic leukaemia Mol. Pathol., February 1, 2002; 55(1): 40 - 45. [Abstract] [Full Text] [PDF]

				A. Hoeflich, R. Reisinger, H. Lahm, W. Kiess, W. F. Blum, H. J. Kolb, M. M. Weber, and E. Wolf Insulin-like Growth Factor-binding Protein 2 in Tumorigenesis: Protector or Promoter? Cancer Res., December 1, 2001; 61(24): 8601 - 8610. [Full Text] [PDF]

				W Zumkeller IGFs and IGFBPs: surrogate markers for diagnosis and surveillance of tumour growth? Mol. Pathol., October 1, 2001; 54(5): 285 - 288. [Abstract] [Full Text] [PDF]

				N. Auersperg, A. S. T. Wong, K.-C. Choi, S. K. Kang, and P. C. K. Leung Ovarian Surface Epithelium: Biology, Endocrinology, and Pathology Endocr. Rev., April 1, 2001; 22(2): 255 - 288. [Abstract] [Full Text]

				C. H. Gravholt, J. Frystyk, A. Flyvbjerg, H. Orskov, and J. S. Christiansen Reduced free IGF-I and increased IGFBP-3 proteolysis in Turner syndrome: modulation by female sex steroids Am J Physiol Endocrinol Metab, February 1, 2001; 280(2): E308 - E314. [Abstract] [Full Text] [PDF]

				H. Yu and T. Rohan Role of the Insulin-Like Growth Factor Family in Cancer Development and Progression J Natl Cancer Inst, September 20, 2000; 92(18): 1472 - 1489. [Abstract] [Full Text] [PDF]

				H. M. Khandwala, I. E. McCutcheon, A. Flyvbjerg, and K. E. Friend The Effects of Insulin-Like Growth Factors on Tumorigenesis and Neoplastic Growth Endocr. Rev., June 1, 2000; 21(3): 215 - 244. [Abstract] [Full Text]

				A. Hoeflich, O. Fettscher, H. Lahm, W. F. Blum, H. J. Kolb, D. Engelhardt, E. Wolf, and M. M. Weber Overexpression of Insulin-like Growth Factor-binding Protein-2 Results in Increased Tumorigenic Potential in Y-1 Adrenocortical Tumor Cells Cancer Res., February 1, 2000; 60(4): 834 - 838. [Abstract] [Full Text]

				T. Ueland, J. Bollerslev, T. B. Hansen, E. N. Ebbesen, L. Mosekilde, K. Brixen, A. Flyvbjerg, and O. Djøseland Increased Cortical Bone Content of Insulin-Like Growth Factors in Acromegalic Patients J. Clin. Endocrinol. Metab., January 1, 1999; 84(1): 123 - 127. [Abstract] [Full Text]